Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Development in Proteomics, Genomics and Imaging System
4.2.2 Rising Investments from Government and Private Players
4.2.3 Increasing Research and Development with Successful Clinical Trials of Biomarkers
4.3 Market Restraints
4.3.1 High Cost of CNS Biomarkers Tests and Diagnostics
4.3.2 Reimbursement and Regulatory Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type of CNS Biomarkers
5.1.1 Safety Biomarker
5.1.2 Efficacy Biomarker
5.1.3 Validation Biomarker
5.1.4 Other
5.2 By Application
5.2.1 Drug Discovery & Development
5.2.2 Personalized Medicine
5.2.3 Others
5.3 By End User
5.3.1 Diagnostic Labs
5.3.2 Clinics/Hospitals
5.3.3 Research Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Acumen Pharmaceuticals Inc.
6.1.2 Alseres Pharmaceuticals Inc.
6.1.3 Aposense Ltd.
6.1.4 Avacta Life Sciences Limited
6.1.5 Banyan Biomarkers Inc.
6.1.6 Bio-Rad Laboratories, Inc.
6.1.7 DiaGenic ASA
6.1.8 G-Biosciences
6.1.9 Merck KGaA
6.1.10 Thermo Fisher Scientific Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS